Previous Article | Next Article 
Infection and Immunity, June 2001, p. 3933-3938, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3933-3938.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Normal Human Fibroblasts Express Pattern
Recognition Receptors for Fungal
(1
3)-
-D-Glucans
Panagiotis
Kougias,1
Duo
Wei,1
Peter J.
Rice,2
Harry E.
Ensley,3
John
Kalbfleisch,4
David L.
Williams,1,5,* and
I. William
Browder1,5
Departments of Surgery,1
Pharmacology,2 and Medical
Education,4 James H. Quillen College of
Medicine, Johnson City, Tennessee 37614; Department of
Chemistry, Tulane University, New Orleans, Louisiana
701153; and James H. Quillen
Veterans Affairs Medical Center, Mountain Home, Tennessee
376145
Received 11 January 2001/Returned for modification 7 February
2001/Accepted 27 February 2001
 |
ABSTRACT |
Fungal cell wall glucans nonspecifically stimulate various aspects
of innate immunity. Glucans are thought to mediate their effects via
interaction with membrane receptors on macrophages, neutrophils, and NK
cells. There have been no reports of glucan receptors on nonimmune
cells. We investigated the binding of a water-soluble glucan in primary
cultures of normal human dermal fibroblasts (NHDF). Membranes from NHDF
exhibited saturable binding with an apparent dissociation constant
(KD) of 8.9 ± 1.9 µg of
protein per ml and a maximum binding of 100 ± 8 resonance units.
Competition studies demonstrated the presence of at least two glucan
binding sites on NHDF. Glucan phosphate competed for all binding sites,
with a KD of 5.6 µM (95% confidence interval [CI], 3.0 to 11 µM), while laminarin competed for 69% ± 6% of binding sites, with a KD of 3.7 µM (95% CI, 1.9 to 7.3 µM). Glucan (1 µg/ml) stimulated
fibroblast NF-
B nuclear binding activity and interleukin 6 (IL-6)
gene expression in a time-dependent manner. NF-
B was activated at 4, 8, and 12 h, while IL-6 mRNA levels were increased by 48% at
8 h. This is the first report of pattern recognition receptors for
glucan on human fibroblasts and the first demonstration of glucan
binding sites on cells other than leukocytes. It also provides the
first evidence that glucans can directly modulate the functional
activity of NHDF. These results provide new insights into the
mechanisms by which the host recognizes and responds to fungal
(1
3)-
-D-glucans and suggests that the response
to glucans may not be confined to cells of the immune system.
 |
INTRODUCTION |
Glucans are
(1
3)-
-D-linked polymers of glucose that are part of
the outer cell wall of saprophytic and pathogenic fungi as well as
certain bacteria (37). Glucans are also released from the
microbial cell wall as exopolymers (14, 23, 28, 37).
Numerous studies have demonstrated that
(1
3)-
-D-glucans will activate a wide array of innate
host defenses (4, 50). This is due, in part, to the
ability of these carbohydrate ligands to activate proinflammatory and
immunoregulatory signaling pathways (NF-
B and NF-interleukin 6 [NF-IL-6]) in immune competent cells by interacting with specific
receptors (1-3, 26, 48). Recent data indicate that
glucans are released from fungal cell walls into the systemic
circulation of patients with systemic or deep fungal infections
(14, 23, 28). It is not clear whether these circulating
fungal polymers induce any of the sequelae associated with fungal
infections. However, the innate immune system has evolved a complex
network of receptors which rapidly identify microorganisms based on the
carbohydrates, lipids, and proteins expressed by the organism
(15, 20, 21). These macromolecular structures are ideal
recognition molecules because they are structurally distinct from those
expressed on the surface of mammalian cells (15, 20, 21,
37). It has been postulated that cell wall glucans may serve as
pattern recognition molecules for the innate immune system (15,
26).
Many species have pattern recognition receptors or binding
proteins which recognize (1
3)-
-D-glucans (10,
17, 26, 27, 30). Ligation of the glucan receptor(s) modulates
immune function and proinflammatory responses in humans and animals
(1-3, 47, 50, 51). In mammals, glucans are thought to
induce biological activity through interaction with receptors on
macrophages (3, 26, 27), neutrophils (34,
43), and NK cells (7, 43, 44). Binding of
(1
3)-
-D-glucan in human and murine monocytes and
macrophages is specific, saturable, and susceptible to displacement by
other (1
3)-
-D-glucans (3, 26, 27). We
have reported the binding and uptake of a variety of water-soluble
(1
3)-
-D-glucans and control polymers with different
physicochemical properties in order to investigate the relationship
between complex polymer structure and receptor binding
(26). We observed that there are multiple glucan receptors
on human monocytes, that these receptors can distinguish between
(1
3)-
-D-glucan polymers, and that large affinity
differences (24 µM to 11 nM) exist between glucan polymers derived
from various sources (26). We also observed that certain glucans appear to interact nonselectively with glucan binding sites,
while other glucans preferentially interact with only one site
(26). The physical and/or functional basis for this
selectively among glucan receptors is not clear.
To the best of our knowledge, there have been no reports of
glucan-specific binding sites on cells other than leukocytes, nor is
there evidence that glucans can directly activate cells other than
immunocytes. In this study we investigated whether normal human dermal
fibroblasts (NHDF) expressed receptors for glucan and, if so, whether
interaction of a highly purified, water-soluble glucan with fibroblasts
activated immunoregulatory and/or proinflammatory intracellular
signaling pathways. We focused on fibroblasts for several reasons.
First, glucans have been reported to accelerate early wound repair
(5, 6, 33). Of greater significance, glucans have been
shown to increase collagen deposition in rodent skin wounds and
intestinal anastomoses (6, 33). We speculated that the
effect of glucan on collagen biosynthesis was indirect, i.e., that
glucan stimulated macrophage release of wound growth factors which
modulated fibroblast collagen biosynthesis (5, 6, 33).
While this was a reasonable hypothesis the data did not preclude a
direct interaction of the ligand with fibroblasts. Second, fibroblasts
are known to respond to microbial recognition patterns, such as
lipopolysaccharide (LPS) (29, 38, 39, 46) and lipoteichoic
acid (38). Recently, Killcullen et al. (16)
have reported that local application of Staphylococcus aureus peptidoglycan increases wound collagen accumulation. van Tol et al. have reported that bacterial peptidoglycan will directly stimulate in vitro expression of collagen
1 (I) and cytokine mRNA
from rodent intestinal myofibroblasts (41). Finally,
fibroblasts have been reported to express Toll-like receptors, which
are crucial signal transducing molecules for LPS, lipoteichoic acid,
and other microbial recognition patterns (39, 46). Taken
together these data indicate that fibroblasts can recognize and, in
some cases, directly respond to macromolecular structures from microbes.
Here, we report the existence of specific glucan binding sites on NHDF.
Interaction of fungal glucan with fibroblast membrane receptors
increases NF-
B activity and proinflammatory cytokine gene
expression. This is the first report of pattern recognition receptors
for glucans on cells other than leukocytes.
 |
MATERIALS AND METHODS |
Carbohydrate polymers
Water-insoluble
(1
3)-
-D-glucan was extracted from
Saccharomyces cerevisiae (49). Insoluble
glucan was converted to a water-soluble form as described by Williams
et al. (49) and chemically characterized as previously
described (11, 19, 24, 25, 49). The final product was
stored (
80°C) as a lyophilized powder. It was dissolved in aqueous
medium and filter sterilized (0.45-µm-pore-size filter) prior to use.
Laminarin is a low-molecular-weight (7,700-g/mol) (1
3)-
-D-glucan polymer which was obtained from Sigma
Chemical Co. (St. Louis, Mo). Laminarin was chemically characterized as described by Mueller et al. (26). Endotoxin contamination
was <0.5 endotoxin unit/mg of carbohydrate as determined by the
endotoxin-specific Endospecy assay (Seigagaku, Tokyo, Japan). We used 1 µg of carbohydrate per ml in the NF-
B and IL-6 mRNA studies.
Therefore, the maximum amount of endotoxin was <0.0005 endotoxin
unit/µg of carbohydrate. This is well below the limit of
detectability and well below the amount that would elicit a response in
our assays.
DAP derivatization of glucans.
Glucan phosphate (85 mg) was
dissolved in 6 ml of dimethyl sulfoxide by stirring for 1 h under
a nitrogen atmosphere. When the (1
3)-
-D-glucan
phosphate was dissolved, 400 ml (355 mg, 4.8 mmol) of
1,3-diaminopropane (DAP) was added. The solution was stirred under
nitrogen, and 35 mg of sodium cyanoborohydride (0.56 mmol) was added.
After an additional 12 h at room temperature, 6 ml of water was
added and the reaction mixture was dialyzed against ultrapure water
using a 1,000-molecular-weight-cutoff membrane. The lyophilized
material was stored at
20°C for later use.
NHDF cell line.
NHDF were obtained by Clonetics (Ogden,
Utah) and maintained in tissue culture with Dulbecco modified Eagle
medium (Mediatech, Washington, D.C.) containing 9%
heat-inactivated calf serum, 1% heat-inactivated fetal bovine serum
(HyClone Corp., Logan, Utah), and 0.2% (vol/vol)
penicillin-streptomycin (Sigma Chemical Co.). The cells were grown as
an adherent culture at 37°C and 5% CO2 tension
in a humidified environment and were harvested according to the
sonication protocol described below.
Isolation of NHDF membranes.
Cells were harvested during the
logarithmic phase of growth, centrifuged at 500 × g
for 10 min, counted, centrifuged again at 500 × g for 10 min, and frozen at
80°C. Cells were thawed in phosphate-buffered
saline in the presence of 10 µl of protease inhibitor cocktail (Sigma
P-8340) per 106 cells. The solution was
maintained at 4°C and sonicated three times at 35% power for 30 s (Sonic Dismembrator; Fisher Scientific, Pittsburgh, Pa.). The samples
were centrifuged at 650 × g for 10 min at 4°C to
spin out nuclei. The pellet was resuspended, sonicated, and
centrifuged. The combined supernatants were centrifuged at 435,000 × g for 30 min at 4°C. The pellet containing NHDF membranes was suspended in Hanks balanced salt solution and assayed using the
bicinchoninic acid protein assay (Pierce, Rockford, Ill.) with bovine
serum albumin standards. Aliquots of the membranes containing 1 mg of
protein/ml were stored in liquid nitrogen for later use.
Binding assays.
Binding assays were performed using a
BIAcore 2000 surface plasmon resonance instrument (Biacore, Piscataway,
N.J.). This technology measures changes in mass as resonance units
(picograms per square millimeter) at a biosensor surface. We
immobilized glucan phosphate on the biosensor and examined its
interactions with membrane proteins and inhibition of the
protein-glucan interaction by the carbohydrates glucan and laminarin.
Samples were maintained at 4°C using an ISOTEMP circulating bath
(Fisher Scientific). Experiments were performed at 37°C using a
running buffer containing 150 mM NaCl, 10 mM HEPES, 3 mM EDTA, and
0.005% surfactant P20 (Biacore).
Attachment of DAP-glucan to the CM-5 sensor chip.
DAP-glucan
phosphate was freshly prepared in 10 mM sodium acetate and adjusted to
a pH of between 8.6 and 8.9 with 1 M NaOH. DAP-glucan was immobilized
to a CM-5 (carboxymethyl dextran) sensor chip on the BIAcore 2000 instrument at a flow rate of 5 µl per min. The sensor surface was
first activated by exposure for 6 min to a freshly prepared solution of
100 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 25 mM
N-hydroxysuccinimide. The surface was then exposed to DAP-glucan (3 mg/ml) for 7 min. This cycle of activation with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-25 mM
N-hydroxysuccinimide and exposure to DAP-glucan phosphate
was repeated five times. Immobilization of DAP-glucan phosphate was
typically about 2,000 resonance units (RU), or 2 ng/mm2. After immobilization, the biosensor
surface was exposed to 1 M ethanolamine (pH 8.5) for 6 min to
inactivate any remaining succinoylated carboxyl groups. The BIAcore
biosensor contains four flow cells; DAP-glucan was immobilized on three
flow cells, while the fourth flow cell served as a control for
nonspecific binding to the dextran surface.
Saturation experiment using the CM-5 sensor chip.
Membranes
prepared from NHDF were suspended at concentrations of 0.012 to 12 µg/ml in HEPES buffer in siliconized vials. A continuous buffer flow
of 25 µl/min was used to establish a baseline measurement of RU.
Assays were performed at 37°C to approximate physiologic conditions.
NHDF membranes were injected for 3 min, followed by continuous flow of
HEPES buffer for 3 min to allow dissociation of membranes from the
carbohydrate surface. At the end of each cycle, the surface was
regenerated by consecutive 1-min exposures to Triton X-100 (0.3%) and
guanidine hydrochloride (3 M) at 100 µl/min. Regeneration resulted in
displacement of
90% of the added RU from the surface.
The BIAcore sensorgram displays the interactions between immobilized
DAP-glucan and membrane receptors in real time. During the initial flow
of buffer, a baseline is established. When the surface is exposed to
NHDF membranes, there is an initial rapid change in the sensorgram due
to the change in refractive index of the solution. This occurs in each
flow cell, including the control which lacks DAP-glucan. This bulk
shift is followed by a concentration-dependent interaction between
DAP-glucan and membrane proteins. When the membrane preparation is
replaced with buffer flowing over the DAP-glucan surface, there is an
equal but opposite bulk shift, followed by dissociation of membrane
from the DAP-glucan surface.
Glucan phosphate competition studies.
A CM-5 chip onto which
DAP-glucan was attached was utilized for the competition experiments.
For competition experiments, samples containing a fixed concentration
of NHDF membranes (10 µg/ml) in the absence and presence of
competitor were alternately injected. NHDF membranes were mixed with
competing carbohydrates for at least 1 h prior to injection on the
BIAcore instrument. After a 3-min dissociation, the surface of the chip
was regenerated with 0.3% Triton X-100 and 3 M guanidine hydrochloride
at 100 µl/min for 1 min (two times). The control sample was then
injected (20 µl/min, 3 min), followed by a new regeneration cycle.
Electrophoretic mobility shift assays.
We employed the gel
shift and supershift assays to assess the activation of NF-
B as well
as the specificity of binding and the contribution of NF-
B
components (p50 and p65) to the activity (2, 3, 45, 47,
48). Briefly, double-stranded consensus binding site
oligonucleotides for NF-
B were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, Calif.). The oligonucleotides were end
labeled with [
-32P]ATP (Amersham, Arlington
Heights, Ill.) using T4 polynucleotide kinase (Promega, Madison, Wis.).
Binding assays were performed in 10 µl of binding reaction mixture
containing 10 µg of nuclear proteins and
32P-labeled NF-
B oligonucleotides. The binding
reaction mixture was incubated at room temperature for 20 min and then
electrophoresed on 4% nondenaturing polyacrylamide gels. The
specificity of binding was confirmed by supershift and competition
assays, which establish the specificity of the binding reaction as well
as the relative contribution of p50-p65 heterodimer. To assess
specificity of binding, a 10-fold excess of cold oligonucleotide was
added. As an additional control, a 10-fold excess of cold
oligonucleotide bearing the AP-II binding site was added to separate
reaction mixtures. To assess the contribution of the NF-
B components
(p50 and p65) to the activity observed, we performed a supershift assay in which antibody to p50, antibody to p65, or antibodies to both p50
and p65 were added to separate reaction mixtures. After polyacrylamide gel electrophoresis, the gels were analyzed by phosphorimaging (Bio-Rad
Laboratories, Hercules, Calif.) followed by drying and exposure to
Kodak X-Omat film at
70°C.
RNA isolation and reverse transcriptase PCR.
Total cellular
RNA was isolated from control and glucan-treated human dermal
fibroblasts using the Ultraspect-II RNA isolation kit (Biotecx,
Houston, Tex.). One microgram of total RNA was used for cDNA synthesis
with murine leukemia virus reverse transcriptase (Perkin-Elmer Inc.,
Branburg, N.J.) in a 20-µl final volume. The cDNA synthesis reaction
was for 15 min at 42°C and 5 min at 99°C. The reaction mixture (2 µl) was subjected to PCR amplification in a mixture (25 µl) that
contained a 1 µM concentration of each of two primers, 1.5 mM
MgCl2, a 0.2 mM concentration of each of four
deoxynucleotides, and 1.25 U of Taq polymerase (Perkin-Elmer Inc.). The upstream primer for human IL-6 was AACTCCTTCTCCACAAGCG. The downstream primer for human IL-6 was
TGGACTGCAGGAACTCCTT. PCR amplification of IL-6 cDNA was
performed under the following conditions: 35 cycles of 45 s at
94°C, 35 s at 54°C, and 45 s at 72°C. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was employed as the gene
transcript control. The PCR data were imaged and quantified by
computer-assisted densitometry and referenced to the gene transcript control.
NF-
B and IL-6 protocol.
NHDF were incubated with glucan
phosphate (1 µg/ml) for various periods of time. NHDF incubated in
medium alone served as the control. At each time point, nuclear protein
was harvested from control or glucan-treated NHDF. Parallel cultures of
NHDF were harvested for total RNA.
Data analysis.
In saturation (see Fig. 1) and competition
(see Fig. 2 and 3) studies, data were normalized to the baseline
established at the start of the experiment and analyzed by unweighted
nonlinear regression using Prism 3.0 (GraphPad Software, Inc., San
Diego, Calif.). Since the bulk shift occurs over approximately 15 s, we estimated the amount of membrane protein bound to the surface by
measuring the increase in RU at 30 s after changing from membrane to buffer exposure. For saturation experiments in which the DAP-glucan phosphate surface was exposed to various concentrations of membrane protein, RU values for each concentration of analyte were analyzed using the model RU = {(RUmax × [analyte])/(KD + [analyte])} + Knonspecific × [analyte], where
RUmax is the maximum binding, KD is the apparent dissociation constant,
Knonspecific is the constant of linear
nonspecific binding, and [analyte] is the protein concentration.
KD values are also accompanied by 95%
confidence intervals (CI) for the apparent
KD.
For competition experiments in which the DAP-glucan phosphate surface
was exposed to a fixed concentration of membrane protein in the absence
or presence of competitor, RU values for each competitor concentration
were further normalized to binding in the absence of competitor (100%)
and analyzed using models for competitive displacement at a single
binding site, a single binding site plus nonspecific binding, and/or
two binding sites. The best model was chosen statistically using the
sequential F test.
Mean values for NF-
B binding activity at time points up to 48 h
(see Fig. 4) were compared by one-way analysis of variance and the
least-significant-difference procedure. Probability levels of 0.05 or
smaller were considered statistically significant.
 |
RESULTS |
NHDF membranes bind to a glucan-coated biosensor
surface.
The NHDF membranes were injected over a concentration
range of 0.012 to 12 mg of protein per ml. This was followed by
exposure of the surface to a continuous flow of buffer (3 min) to allow dissociation of the analyte from the ligand. The bulk shift occurs over
15 s in the control flow cell, so we chose to measure responses 30 s after the end of the analyte injection (Fig.
1). The binding response as a function of
the NHDF membrane protein concentration was proportional to the
immobilized DAP-glucan attached to the flow channels. The apparent
KD was 8.9 ± 1.9 µg of protein/ml, and the maximum binding was 100 ± 8 RU. Nonspecific binding was not significant at the protein concentrations which were used.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Saturation curve for NHDF membrane binding to
immobilized DAP-glucan, showing results from a typical experiment where
averages were obtained from three flow cells and five cycles.
|
|
Glucan phosphate completely inhibits binding of NHDF to a
glucan-coated sensor surface.
Glucan phosphate completely
inhibited the binding of NHDF membranes to a glucan phosphate biosensor
surface with characteristics of a single binding site (Fig.
2). The KD
for the inhibition was 5.6 µM (95% CI, 3.0 to 11.0 µM),
corresponding to a concentration of 0.88 µg of glucan phosphate per
ml.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Glucan phosphate competition for NHDF binding to
immobilized DAP-glucan phosphate. The displacement relationship was
characteristic of a single binding site with a
KD of 5.6 µM (95% CI, 3 to 11 µM).
|
|
Laminarin partially inhibits binding of NHDF membranes to a
glucan-coated sensor surface.
Using a cell-based receptor ligand
assay, we have observed that laminarin will bind to a subset of
(1
3)-
-D-glucan receptors on the human U937 monocyte
cell line (26). We have confirmed and extended this
observation using surface plasmon resonance and U937 membranes (E. Lowe
et al., submitted for publication). In the present study,
laminarin partially inhibited the binding of NHDF membranes to the
glucan phosphate biosensor surface with characteristics of a single
binding site (Fig. 3). Laminarin could inhibit only 69% ± 6% of the binding of NHDF membranes to glucan phosphate. The KD for the inhibition by
laminarin was 3.7 µM (95% CI, 1.9 to 7.3 µM), corresponding to a
concentration of 0.028 µg/ml. The ability of laminarin to inhibit
only a fraction of the binding interactions suggests that there are at
least two types of interactions between NHDF membranes and glucan
phosphate. Laminarin is able to distinguish and inhibit the interaction
at one of the sites, while glucan phosphate interacts with both sites.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
Laminarin competition for NHDF binding to immobilized
DAP-glucan phosphate. The displacement relationship was characteristic
of a single binding site with a KD of
3.7 µM (95% CI, 1.9 to 7.3 µM) and a maximum displacement of 69% ± 6%. The failure of laminarin to completely inhibit the interaction
of NHDF and immobilized DAP-glucan phosphate suggests the presence of
two types of binding interactions, one of which is not inhibitable by
laminarin.
|
|
Coincubation with glucan phosphate increases NHDF NF-
B
activity and IL-6 mRNA expression.
Glucan stimulated NF-
B
nuclear binding activity and IL-6 mRNA expression in a time-dependent
manner. NF-
B was activated at 4 (102%), 8 (131%), and 12 (85%) h
(Fig. 4). NDHF were treated for 8 h
with glucan phosphate (1 µg/ml). Reverse transcriptase PCR data
indicate that IL-6 mRNA levels were increased by 48% at 8 h (Fig.
5).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Treatment of human fibroblasts with glucan phosphate (1 µg/ml) results in a time-dependent increase in NF- B nuclear
binding activity. The data are shown as a graph of normalized
integrated intensity. A representative gel shift assay is shown in the
inset. The density (integrated intensity) of the band is directly
proportional to the degree of NF- B nuclear binding and activity. The
time is given below each lane in the gel. The gels are quantified by
computer-assisted scanning density, and the data are presented as
means ± standard errors, with an n value of 3 per
time point. The data are normalized to the zero time point value, which
was set at 1.0. *, P < 0.05.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 5.
Time-dependent increase in IL-6 mRNA levels in NHDF
treated with glucan phosphate (1 mg/ml). A representative IL-6 PCR
product gel is shown above the graph. The gels were imaged, and the
integrated intensity (I.I.) was determined. The IL-6 data were
normalized to the GAPDH transcript control. The data are presented as
normalized integrated intensity.
|
|
 |
DISCUSSION |
A number of significant observations have emerged from this study.
First and foremost, we found that NDHF express membrane receptors for
(1
3)-
-D-glucans. To the best of our knowledge, this
is the first report of glucan-specific receptors on cells other than
leukocytes. Second, interaction of glucan with membrane receptors on
NDHF activates NF-
B, an important intracellular signaling pathway
which is associated with regulation of cytokine and chemokine gene
expression. This is consistent with previous studies which have shown
that glucans stimulate transcription factor activation in macrophages
and neutrophils (1-3). Third, glucan receptor
interactions in NHDF resulted in increased IL-6 mRNA expression.
Previous studies have reported increased cytokine gene upregulation in
macrophages treated with glucans (13, 18, 31). However,
other studies have reported activation of immunocyte NF-
B by glucans
without cytokine gene upregulation (45), while still other
investigators have reported cytokine downregulation in response to
glucan and proinflammatory stimuli (36, 47, 48). It is not
clear whether this relates to the glucan used, the cytokines examined,
the cells or tissues studied, or other factors.
We observed that binding of glucan by NHDF membranes was saturable,
dose dependent, and specific. Competition for this interaction by
glucan phosphate was complete and had a KD
of 5.6 µM (95% CI, 3.0 to 11.0 µM). This is very similar to the
KD of 5.2 µM (95% CI, 0.8 to 7.1 µM)
for the human U937 promonocytic cell line (unpublished observation).
Interestingly, laminarin competition for this interaction was able to
displace a maximum of 69% ± 6% of the interaction, with a
KD of 3.7 µM (95% CI, 1.9 to 7.3 µM).
Laminarin is equipotent with glucan phosphate based on molar
concentration, but its lower molecular weight makes it more potent (28 versus 880 ng/ml). The fact that laminarin cannot completely inhibit
the interaction of NHDF membranes with immobilized glucan phosphate
suggests the presence of at least two different binding sites for
glucan phosphate on NHDF membranes. Laminarin selectively interacts
with one site, while glucan phosphate interacts with both sites. We
have reported similar results using the human U937 promonocytic cell
line, where laminarin displaced 61% ± 4% of binding, with a
KD of 2.6 µM (95% CI, 1.7 to 4.2 µM),
and glucan phosphate completely inhibited binding in a dose-dependent
manner (Lowe et al., submitted). The similarity in the affinities of
these interactions in human promonocytes and fibroblasts suggests that
similar receptors are present in both cell types. The data also
strengthen the contention that there are multiple binding sites for glucans.
While there are numerous reports that monocytes, macrophages,
neutrophils, and NK cells express membrane pattern recognition receptors for (1
3)-
-D-glucan, the precise nature of
the glucan receptor(s) is the subject of controversy. Di Renzo et al.
(7), Thornton et al. (40), and Vetvicka et
al. (43) have reported that the type 3 complement receptor
(CR3 [also known as CD11b or CD18]) is a glucan binding site
on macrophages, neutrophils, and NK cells. The glucan binding is
reported to be through one or more lectin sites located outside the
CD11b I domain (40, 43, 44). Duan et al. (8),
Di Renzo et al. (7), and Vetvicka et al. (43,
44) have reported a
-glucan binding lectin on NK cells which
contributes to NK cell-mediated cytotoxicity. Zimmerman et al. reported
that lactosylceramide binds PGG-glucan (a proprietary glucan)
and that this glycosphingolipid may be a leukocyte glucan binding
moiety (52). Dushkin et al. (9) and
Vereschagin et al. (42) have reported that a
carboxymethylated glucan binds to the macrophage scavenger receptor. We
have reported the presence of two glucan binding sites on U937 cells
which stimulate intracellular signaling pathways culminating in the
activation, translocation, and nuclear binding of immunoregulatory and
proinflammatory transcriptional activator proteins (3,
26). Our data suggest that neither of these sites is CR3
(26). Michalek et al. have extended this observation by
reporting that PGG-glucan also binds to a site distinct from CR3
(22). Whether PGG-glucan and the glucans described in this
study bind to the same site(s) is not known. CR3 is a
2 integrin
which is leukocyte restricted (35), and it is involved in
the recognition of microbial molecular patterns, such as LPS (32). However, fibroblasts have not been reported to
express CR3, and thus the binding and functional activation of
fibroblasts by glucan cannot be attributed to a CR3-dependent
mechanism. This does not diminish the potential importance of CR3 as a
leukocyte binding moiety for glucans; rather, it reinforces the notion
that there are multiple glucan binding sites and it indicates that glucan receptors are not sequestered solely in leukocytes, suggesting that these receptors may be more widespread than previously thought. Whether there are glucan receptors on cells other than fibroblasts, macrophages, neutrophils, and NK cells remains to be established. In
addition, it is not clear whether the two binding sites which we have
identified on human monocytes and fibroblasts activate the same or
different signaling pathways within the cell. We are currently
investigating both of these questions.
In conclusion, we have identified at least two specific glucan binding
sites on NHDF. The interaction of the glucan ligand with NHDF results
in the activation of proinflammatory intracellular signaling pathways
and upregulation of cytokine gene expression. This is the first report
of a glucan binding site on cells other than leukocytes. The potential
ramifications of these data are significant because they force us to
reexamine the current hypotheses regarding the mechanisms by which the
host recognizes and responds to these fungal cell wall carbohydrates.
By way of example, glucans have been reported to exert a plethora of
nonspecific effects on immune function (4, 50). The
presumed mechanism was that glucans interact with leukocytes and other
elements of innate immunity, resulting in either a primed or activated
state (1, 12, 36). The systemic effects were attributed to
release of proinflammatory and/or immunoregulatory mediators which
serve as second messengers; i.e., the systemic effects were indirect. While this is a reasonable explanation for the observed effects, the
present data suggest that glucans may also directly interact with and
modify the functional state of cells such as fibroblasts. Since
fibroblasts are present in many organ systems, it is reasonable to
speculate that some of the nonspecific effects which have been ascribed
to glucans may be more direct than previously thought.
 |
ACKNOWLEDGMENTS |
This material is based on work supported by an Office of Research
and Development, Department of Veterans Affairs, Merit Review grant to
I.W.B. This work was also supported, in part, by Public Health Service
grant GM53522 from the National Institute of General Medical Sciences
to D.L.W.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Surgery, James H. Quillen College of Medicine, East Tennessee State
University, P.O. Box 70575, Johnson City, TN 37614-0575. Phone: (423)
439-6363. Fax: (423) 439-6259. E-mail: williamd{at}etsu.edu.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Adams, D. S.,
R. Nathans,
S. C. Pero,
A. Sen, and E. Wakshull.
2000.
Activation of a Rel-A/CEBP-beta-related transcription factor heteromer by PGG-glucan in a murine monocytic cell line.
J. Cell. Biochem.
77:221-233[CrossRef][Medline].
|
| 2.
|
Adams, D. S.,
S. C. Pero,
J. B. Petro,
R. Nathans,
W. M. Mackin, and E. Wakshull.
1997.
PGG-glucan activates NF- B-like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line.
J. Leukoc. Biol.
62:865-873[Abstract].
|
| 3.
|
Battle, J.,
T. Ha,
C. Li,
V. Della Beffa,
P. Rice,
J. Kalbfleisch,
W. Browder, and D. Williams.
1998.
Ligand binding to the (1 3)-beta-D-glucan receptor stimulates NF B activation, but not apoptosis in U937 cells.
Biochem. Biophys. Res. Commun.
249:499-504[CrossRef][Medline].
|
| 4.
|
Bohn, J. A., and J. N. BeMiller.
1995.
(1 3)-Beta-D-glucans as biological response modifiers: a review of structure-functional activity relationships.
Carbohydr. Polym.
28:3-14.
|
| 5.
|
Browder, W.,
D. Williams,
P. Lucore,
H. Pretus,
E. Jones, and R. McNamee.
1988.
Effect of enhanced macrophage function on early wound healing.
Surgery
104:224-230[Medline].
|
| 6.
|
Compton, R.,
D. Williams, and W. Browder.
1996.
The beneficial effect of enhanced macrophage function on the healing of bowel anastomoses.
Am. Surg.
62:14-18[Medline].
|
| 7.
|
Di Renzo, L.,
E. Yefenof, and E. Klein.
1991.
The function of human NK cells is enhanced by -glucan, a ligand of CR3 (CD11b/CD18).
Eur. J. Immunol.
21:1755-1758[Medline].
|
| 8.
|
Duan, X.,
M. Ackerly,
E. Vivier, and P. Anderson.
1994.
Evidence for involvement of beta-glucan-binding cell surface lectins in human natural killer cell function.
Cell. Immunol.
157:393-402[CrossRef][Medline].
|
| 9.
|
Dushkin, I. M.,
A. F. Safina,
E. I. Vereschagin, and Y. S. Schwartz.
1996.
Carboxymethylated beta-1,3-glucan inhibits the binding and degradation of acetylated low density lipoproteins in macrophages in vitro and modulates their plasma clearance in vivo.
Cell Biochem. Funct.
14:209-217[Medline].
|
| 10.
|
Engstad, R. E., and B. Robertsen.
1994.
Specificity of a beta-glucan receptor on macrophages from Atlantic salmon (Salmo salar L.).
Dev. Comp. Immunol.
18:397-408[CrossRef][Medline].
|
| 11.
|
Ensley, H. E.,
B. Tobias,
H. A. Pretus,
R. B. McNamee,
E. L. Jones,
I. W. Browder, and D. L. Williams.
1994.
NMR spectral analysis of a water-insoluble (1-3)- -D-glucan isolated from Saccharomyces cerevisiae.
Carbohydr. Res.
258:307-311[CrossRef][Medline].
|
| 12.
|
Falch, B. H.,
T. Espevik,
L. Ryan, and B. T. Stokke.
2000.
The cytokine stimulating activity of (1 3)- -D-glucans is dependent on the triple helix conformation.
Carbohydr. Res.
329:587-596[CrossRef][Medline].
|
| 13.
|
Hirata, N.,
A. Tsuzkui,
N. Ohno,
M. Saita,
Y. Adachi, and T. Yadomae.
1998.
Cytokine synthesis of human monocytes stimulated by triple or single helical conformer of an antitumour (1 3)-beta-D-glucan preparation, sonifilan.
Zentbl. Bakteriol.
288:403-413.
|
| 14.
|
Hiyoshi, M.,
S. Tagawa,
S. Hashimoto,
C. Sakamoto, and N. Tatsumi.
1999.
Evaluation of a new laboratory test measuring plasma (1 3)-beta-D-glucan in the diagnosis of Candida deep mycosis: comparison with a serologic test.
Kansenshogaku Zasshi
73:1-6[Medline].
|
| 15.
|
Janeway, C. A., Jr., and R. Medzhitov.
1999.
Lipoproteins take their Toll on the host.
Curr. Biol.
9:R879-R882[CrossRef][Medline].
|
| 16.
|
Killcullen, J. K.,
Q. P. Ly,
T. H. Chang,
S. M. Levenson, and J. J. Steinberg.
1998.
Nonviable Staphylococcus aureus and its peptidoglycan stimulate macrophage recruitment, angiogenesis, fibroplasia and collagen accumulation in wounded rats.
Wound Repair Regen.
6:149-156[CrossRef][Medline].
|
| 17.
|
Lee, S. Y.,
R. Wang, and K. Soderhall.
2000.
A lipopolysaccharide- and beta-1,3-glucan-binding protein from hemocytes of the freshwater crayfish Pacifastacus leniusculus. Purification, characterization, and cDNA cloning.
J. Biol. Chem.
275:1337-1343[Abstract/Free Full Text].
|
| 18.
|
Ljungman, A. G.,
P. Leanderson, and C. Tagesson.
1998.
(1 3)-Beta-D-glucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages.
Environ. Toxicol. Pharmacol.
5:273-281.
|
| 19.
|
Lowman, D.,
H. Ensley, and D. Williams.
1998.
Identification of phosphate substitution sites by NMR spectroscopy in a water-soluble phosphorylated (1 3)- -D-glucan.
Carbohydr. Res.
306:559-562[CrossRef].
|
| 20.
|
Medzhitov, R., and C. A. Janeway.
1998.
Self-defense: the fruit fly style.
Proc. Natl. Acad. Sci. USA
95:429-430[Free Full Text].
|
| 21.
|
Medzhitov, R., and C. A. Janeway.
2000.
An ancient system of host defense.
Curr. Opin. Immunol.
10:12-15.
|
| 22.
|
Michalek, M.,
D. Melican,
D. Brunke-Reese,
M. Langevin,
K. Lemerise,
W. Galbraith,
M. Patchen, and W. Mackin.
1998.
Activation of rat macrophages by betafectin PGG-glucan requires cross-linking of membrane receptors distinct from complement receptor three (CR3).
J. Leukoc. Biol.
64:337-344[Abstract].
|
| 23.
|
Mori, T.,
H. Ikemoto,
M. Matsumura,
M. Yoshida,
K. Inada,
S. Endo,
A. Ito,
S. Watanabe,
H. Yamaguchi,
M. Mitsuya,
M. Kodama,
T. Tani,
T. Yokota,
T. Kobayashi,
J. Kambayashi,
T. Nakamura,
T. Masaoka,
H. Teshima,
T. Yoshinaga,
S. Kohno,
K. Hara, and S. Miyazaki.
1997.
Evaluation of plasma (1 3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections.
Eur. J. Clin. Chem. Biochem.
35:553-560.
|
| 24.
|
Mueller, A.,
W. Mayberry,
R. Acuff,
S. Thedford,
W. Browder, and D. Williams.
1994.
Lipid content of macroparticulate (1 3)-beta-D-glucan isolated from Saccharomyces cerevisiae.
Microbios
79:253-261[Medline].
|
| 25.
|
Mueller, A.,
H. Pretus,
R. McNamee,
E. Jones,
I. Browder, and D. Williams.
1995.
Comparison of the carbohydrate biological response modifiers Krestin, schizophyllan and glucan phosphate by aqueous size exclusion chromatography with in-line argon-ion multi-angle laser light scattering photometry and differential viscometry detectors.
J. Chromatogr. B
666:283-290[CrossRef][Medline].
|
| 26.
|
Mueller, A.,
J. Raptis,
P. J. Rice,
J. H. Kalbfleisch,
R. D. Stout,
H. E. Ensley,
W. Browder, and D. L. Williams.
2000.
The influence of glucan polymer structure and solution conformation on binding to (1 3)- -D-glucan receptors in a human monocyte-like cell line.
Glycobiology
10:339-346[Abstract/Free Full Text].
|
| 27.
|
Mueller, A.,
P. J. Rice,
H. E. Ensley,
P. S. Coogan,
J. H. Kalbfleisch,
J. L. Kelley,
E. J. Love,
C. A. Portera,
T. Ha,
I. W. Browder, and D. L. Williams.
1996.
Receptor binding and internalization of water-soluble (1 3)-beta-D-glucan biologic response modifier in two monocyte/macrophage cell lines.
J. Immunol.
156:3418-3425[Abstract].
|
| 28.
|
Nakamura, Y.,
S. Tazawa, and M. Tsutiya.
1998.
The clinical significance of plasma (1 3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test for fungal febrile episodes.
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi
9:33-39[Medline].
|
| 29.
|
Nemoto, E.,
S. Sugawara,
H. Tada,
H. Takada,
H. Shimauchi, and H. Horiuchi.
2000.
Cleavage of CD14 on human gingival fibroblasts cocultured with activated neutrophils is mediated by human leukocyte elastase resulting in down-regulation of lipopolysaccharide-induced IL-8 production.
J. Immunol.
165:5807-5813[Abstract/Free Full Text].
|
| 30.
|
Ochiai, M., and M. Ashida.
2000.
A pattern-recognition protein for beta-1,3-glucan. The binding domain and the cDNA cloning of beta-1,3-glucan recognition protein from the silkworm, Bombyx mori.
J. Biol. Chem.
275:4995-5002[Abstract/Free Full Text].
|
| 31.
|
Okazaki, M.,
Y. Adachi,
N. Ohno, and T. Yadomae.
1995.
Structure-activity relationship of (1 3)- -D-glucans in the induction of cytokine production from macrophages in vitro.
Biol. Pharm. Bull.
18:1320-1327[Medline].
|
| 32.
|
Perera, P. Y.,
T. N. Mayadas,
O. Takeuchi,
S. Akira,
M. Zaks-Zilberman,
S. M. Goyert, and S. N. Vogel.
2001.
CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TOR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression.
J. Immunol.
166:574-581[Abstract/Free Full Text].
|
| 33.
|
Portera, C. A.,
E. J. Love,
L. Memore,
L. Zhang,
A. Mueller,
W. Browder, and D. L. Williams.
1997.
Effect of macrophage stimulation on collagen biosynthesis in the healing wound.
Am. Surg.
63:125-131[Medline].
|
| 34.
|
Ross, G. D.,
J. A. Cain,
B. L. Myones,
S. L. Newman, and P. J. Lachmann.
1987.
Specificity of membrane complement receptor type three (CR3) for -glucans.
Complement
4:61-74[Medline].
|
| 35.
|
Ross, G. D., and V. Vetvicka.
1993.
CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions.
Clin. Exp. Immunol.
92:181-184[Medline].
|
| 36.
|
Soltys, J., and M. T. Quinn.
1999.
Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan.
Infect. Immun.
67:244-252[Abstract/Free Full Text].
|
| 37.
|
Stone, B. A., and A. E. Clarke.
1992.
Chemistry and biology of (1 3)- -glucan, p. 283-363.
La Trobe University Press, Melbourne, Australia.
|
| 38.
|
Sugawara, S.,
R. Arakaki,
H. Rikiishi, and H. Takada.
1999.
Lipoteichoic acid acts as an antagonist and an agonist of lipopolysaccharide on human gingival fibroblasts and monocytes in a CD14-dependent manner.
Infect. Immun.
67:1623-1632[Abstract/Free Full Text].
|
| 39.
|
Tabeta, K.,
K. Yamazaki,
S. Akashi,
K. Miyake,
H. Kumada,
T. Umemoto, and H. Yoshie.
2000.
Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts.
Infect. Immun.
68:3731-3735[Abstract/Free Full Text].
|
| 40.
|
Thornton, B. P.,
V. Vetvicka,
M. Pitman,
R. C. Goldman, and G. D. Ross.
1996.
Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
J. Immunol.
156:1235-1246[Abstract].
|
| 41.
|
van Tol, E. A. F.,
L. Holt,
F. L. Li,
F. M. Kong,
T. Rippe,
M. Yamauchi,
J. Pucilowska,
P. K. Lund, and R. B. Sartor.
1999.
Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts.
Am. J. Physiol.
277:G245-G255[Abstract/Free Full Text].
|
| 42.
|
Vereschagin, E. I.,
A. A. Van Lambalgen,
M. I. Dushkin,
Y. S. Schwartz,
L. Polyakov,
A. Heemskerk,
E. Huisman,
L. G. Thijs, and G. C. Van den Bos.
1998.
Soluble glucan protects against endotoxin shock in the rat: the role of the scavenger receptor.
Shock
9:193-198[Medline].
|
| 43.
|
Vetvicka, V.,
B. P. Thornton, and G. D. Ross.
1996.
Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
J. Clin. Invest.
98:50-61[Medline].
|
| 44.
|
Vetvicka, V.,
B. P. Thornton,
J. Wieman, and G. D. Ross.
1997.
Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3.
J. Immunol.
159:599-605[Abstract].
|
| 45.
|
Wakshull, E.,
D. Brunke-Reese,
J. Lindermuth,
L. Fisette,
R. S. Nathans,
J. J. Crowley,
J. C. Tufts,
J. Zimmerman,
W. Mackin, and D. S. Adams.
1999.
PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappaB-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor.
Immunopharmacology
41:89-107[CrossRef][Medline].
|
| 46.
|
Wang, P. L.,
Y. Azuma,
M. Shinohara, and K. Ohura.
2000.
Toll-like receptor 4-mediated signal pathway induced by Porphyromonas gingivalis lipopolysaccharide in human gingival fibroblasts.
Biochem. Biophys. Res. Commun.
273:1161-1167[CrossRef][Medline].
|
| 47.
|
Williams, D. L.,
T. Ha,
C. Li,
J. H. Kalbfleisch,
J. J. Laffan, and D. A. Ferguson.
1999.
Inhibiting early activation of tissue nuclear factor- B and nuclear factor interleukin 6 with (1 3)- -D-glucan increases long-term survival in polymicrobial sepsis.
Surgery
126:54-65[CrossRef][Medline].
|
| 48.
|
Williams, D. L.,
T. Ha,
C. Li,
J. Laffan,
J. Kalbfleisch, and W. Browder.
2000.
Inhibition of LPS induced NF B activation by a glucan ligand involves down regulation of IKK kinase activity and altered phosphorylation and degradation of I B .
Shock
13:446-452[Medline].
|
| 49.
|
Williams, D. L.,
R. B. McNamee,
E. L. Jones,
H. A. Pretus,
H. E. Ensley,
I. W. Browder, and N. R. Di Luzio.
1991.
A method for the solubilization of a (1 3)- -D-glucan isolated from Saccharomyces cerevisiae.
Carbohydr. Res.
219:203-213[CrossRef][Medline].
|
| 50.
|
Williams, D. L.,
A. Mueller, and W. Browder.
1996.
Glucan-based macrophage stimulators: a review of their anti-infective potential.
Clin. Immunother.
5:392-399.
|
| 51.
|
Williams, D. L.,
H. A. Pretus,
R. B. McNamee,
E. L. Jones,
H. E. Ensley,
I. W. Browder, and N. R. Di Luzio.
1991.
Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae.
Immunopharmacology
22:139-156[CrossRef][Medline].
|
| 52.
|
Zimmerman, J. W.,
J. Lindermuth,
P. A. Fish,
G. P. Palace,
T. T. Stevenson, and D. E. DeMong.
1998.
A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes.
J. Biol. Chem.
273:22014-22020[Abstract/Free Full Text].
|
Infection and Immunity, June 2001, p. 3933-3938, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3933-3938.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Adams, E. L., Rice, P. J., Graves, B., Ensley, H. E., Yu, H., Brown, G. D., Gordon, S., Monteiro, M. A., Papp-Szabo, E., Lowman, D. W., Power, T. D., Wempe, M. F., Williams, D. L.
(2008). Differential High-Affinity Interaction of Dectin-1 with Natural or Synthetic Glucans Is Dependent upon Primary Structure and Is Influenced by Polymer Chain Length and Side-Chain Branching. J. Pharmacol. Exp. Ther.
325: 115-123
[Abstract]
[Full Text]
-
Kelly, M. M., McNagny, K., Williams, D. L., van Rooijen, N., Maxwell, L., Gwozd, C., Mody, C. H., Kubes, P.
(2008). The Lung Responds to Zymosan in a Unique Manner Independent of Toll-Like Receptors, Complement, and Dectin-1. Am. J. Respir. Cell Mol. Bio.
38: 227-238
[Abstract]
[Full Text]
-
Ozment-Skelton, T. R., Goldman, M. P., Gordon, S., Brown, G. D., Williams, D. L.
(2006). Prolonged Reduction of Leukocyte Membrane-Associated Dectin-1 Levels following beta-Glucan Administration. J. Pharmacol. Exp. Ther.
318: 540-546
[Abstract]
[Full Text]
-
Rice, P. J., Adams, E. L., Ozment-Skelton, T., Gonzalez, A. J., Goldman, M. P., Lockhart, B. E., Barker, L. A., Breuel, K. F., DePonti, W. K., Kalbfleisch, J. H., Ensley, H. E., Brown, G. D., Gordon, S., Williams, D. L.
(2005). Oral Delivery and Gastrointestinal Absorption of Soluble Glucans Stimulate Increased Resistance to Infectious Challenge. J. Pharmacol. Exp. Ther.
314: 1079-1086
[Abstract]
[Full Text]
-
Lebron, F., Vassallo, R., Puri, V., Limper, A. H.
(2003). Pneumocystis carinii Cell Wall {beta}-Glucans Initiate Macrophage Inflammatory Responses through NF-{kappa}B Activation. J. Biol. Chem.
278: 25001-25008
[Abstract]
[Full Text]
-
Taylor, P. R., Brown, G. D., Reid, D. M., Willment, J. A., Martinez-Pomares, L., Gordon, S., Wong, S. Y. C.
(2002). The {beta}-Glucan Receptor, Dectin-1, Is Predominantly Expressed on the Surface of Cells of the Monocyte/Macrophage and Neutrophil Lineages. J. Immunol.
169: 3876-3882
[Abstract]
[Full Text]
-
Rice, P. J., Kelley, J. L., Kogan, G., Ensley, H. E., Kalbfleisch, J. H., Browder, I. W., Williams, D. L.
(2002). Human monocyte scavenger receptors are pattern recognition receptors for (1->3)-{beta}-D-glucans. J. Leukoc. Biol.
72: 140-146
[Abstract]
[Full Text]
-
Cenci, E., Mencacci, A., Spreca, A., Montagnoli, C., Bacci, A., Perruccio, K., Velardi, A., Magliani, W., Conti, S., Polonelli, L., Romani, L.
(2002). Protection of Killer Antiidiotypic Antibodies against Early Invasive Aspergillosis in a Murine Model of Allogeneic T-Cell-Depleted Bone Marrow Transplantation. Infect. Immun.
70: 2375-2382
[Abstract]
[Full Text]
-
Bozza, S., Gaziano, R., Spreca, A., Bacci, A., Montagnoli, C., di Francesco, P., Romani, L.
(2002). Dendritic Cells Transport Conidia and Hyphae of Aspergillus fumigatus from the Airways to the Draining Lymph Nodes and Initiate Disparate Th Responses to the Fungus. J. Immunol.
168: 1362-1371
[Abstract]
[Full Text]